ArticleJACC. Advances2024
Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy.
Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies.European heart journal. Cardiovascular pharmacotherapy · 2025Pooled it
- Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis.European journal of clinical investigation · 2025Pooled it
- Rare Hereditary Cardiac Amyloidosis Treated With SGLT2 Inhibitor: Beyond ATTR/AL.JACC. Case reports · 2026Article
- Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy.Journal of the American Heart Association · 2026Article
- Expanding the scope of SGLT inhibitors in underrepresented cardiac populations: from pathophysiology to clinical evidence.Frontiers in cardiovascular medicine · 2026Review
- SGLT2 inhibitors in cardiac amyloidosis: mechanistic insights and clinical perspectives-a narrative review.Cardiovascular diabetology. Endocrinology reports · 2025Review
- SGLT-2 inhibitors for cardiac amyloidosis: Hype or hope?European journal of clinical investigation · 2025Article
- The Impact of Diagnostic Code and Inclusion Period on Clinical Outcomes in ATTR Cardiomyopathy.JACC. Advances · 2025Article
- Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Amyloidosis With or Without Heart Failure.The American journal of medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.